

The listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Previously Presented) A method for the treatment of cancerous cell growth comprising administering a compound of formula I



wherein B is phenyl substituted by -Y-Ar and optionally substituted by one or more substituents independently selected from the group consisting of halogen, up to per-halosubstitution, and  $X_n$ , wherein n is 0-3 and each X is independently selected from the group consisting of -CN,  $-\text{CO}_2\text{R}^5$ ,  $-\text{C}(\text{O})\text{NR}^5\text{R}^{5'}$ ,  $-\text{C}(\text{O})\text{R}^5$ ,  $-\text{NO}_2$ ,  $-\text{OR}^5$ ,  $-\text{SR}^5$ ,  $-\text{NR}^5\text{R}^{5'}$ ,  $-\text{NR}^5\text{C}(\text{O})\text{OR}^{5'}$ ,  $-\text{NR}^5\text{C}(\text{O})\text{R}^{5'}$ ,  $\text{C}_1\text{-C}_{10}$  alkyl,  $\text{C}_2\text{-C}_{10}$  alkenyl,  $\text{C}_1\text{-C}_{10}$  alkoxy,  $\text{C}_3\text{-C}_{10}$  cycloalkyl, phenyl, pyridinyl, naphthyl, isoquinolinyl, quinolinyl up to per halo-substituted  $\text{C}_1\text{-C}_{10}$  alkyl, up to per halo-substituted  $\text{C}_2\text{-C}_{10}$  alkenyl, up to per halo-substituted  $\text{C}_1\text{-C}_{10}$  alkoxy, up to per halo-substituted  $\text{C}_3\text{-C}_{10}$  cycloalkyl;


wherein  $\text{R}^5$  and  $\text{R}^{5'}$  are independently selected from H,  $\text{C}_1\text{-C}_{10}$  alkyl,  $\text{C}_2\text{-C}_{10}$  alkenyl,  $\text{C}_3\text{-C}_{10}$  cycloalkyl, up to per-halosubstituted  $\text{C}_1\text{-C}_{10}$  alkyl, up to per-halosubstituted  $\text{C}_2\text{-C}_{10}$  alkenyl and up to per-halosubstituted  $\text{C}_3\text{-C}_{10}$  cycloalkyl,

wherein Y is -O-, or -S-,

Ar is phenyl, or pyridinyl, optionally substituted by halogen up to per-halosubstitution and optionally substituted by  $Z_{n1}$ , wherein n1 is 0 to 3 and each Z is independently selected from the group consisting of -CN, =O,  $-\text{CO}_2\text{R}^5$ ,  $-\text{C}(\text{O})\text{NR}^5\text{R}^{5'}$ ,  $-\text{C}(\text{O})\text{NR}^5$ ,  $-\text{NO}_2$ ,  $-\text{OR}^5$ ,  $-\text{SR}^5$ ,  $-\text{NR}^5\text{R}^{5'}$ ,  $-\text{NR}^5\text{C}(\text{O})\text{OR}^{5'}$ ,  $-\text{C}(\text{O})\text{R}^5$ ,  $-\text{NR}^5\text{C}(\text{O})\text{R}^{5'}$ ,  $-\text{SO}_2\text{R}^5$ ,  $\text{SO}_2\text{NR}^5\text{R}^{5'}$ ,  $\text{C}_1\text{-C}_{10}$  alkyl,  $\text{C}_1\text{-C}_{10}$  alkoxy,  $\text{C}_3\text{-C}_{10}$  cycloalkyl, up to per halo-substituted  $\text{C}_1\text{-C}_{10}$  alkyl, and up to per halo-substituted  $\text{C}_3\text{-C}_{10}$  cycloalkyl,

and


A is a heteroaryl moiety selected from the group consisting of



wherein

$R^1$  is selected from the group consisting of halogen,  $C_3$ - $C_{10}$  alkyl,  $C_3$ - $C_{10}$  cycloalkyl,  $C_1$ - $C_{13}$  heteroaryl,  $C_6$ - $14$  aryl,  $C_7$ - $24$  alkaryl, up to per-halosubstituted  $C_1$ - $C_{10}$  alkyl, up to per-halosubstituted  $C_3$ - $C_{10}$  cycloalkyl, up to per-halosubstituted  $C_1$ - $C_{13}$  heteroaryl, up to per-halosubstituted  $C_6$ - $14$  aryl, and up to per-halosubstituted  $C_7$ - $24$  alkaryl;

$R^c$  is hydrogen, halogen,  $C_1$ - $C_{10}$  alkyl, up to per-halosubstituted  $C_1$ - $C_{10}$  alkyl or combines with  $R^1$  and the ring carbon atoms to which  $R^1$  and  $R^c$  are bound to form a 5- or 6-membered cycloalkyl, aryl or hetaryl ring with 0-2 members selected from O, N and S; subject to the proviso that where A is




B is not




wherein  $n = 2-4$ ,

or



2-8. (Cancelled)

9. (Original) A method as in claim 1 comprising administering a compound of the formula



wherein  $R^1$  and B are as defined in claim 1.


10. (Cancelled)

11. (Previously Presented) A method as in claim 1 comprising administering a compound selected from the group consisting of:

*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(4-hydroxyphenyl)oxyphenyl)urea;  
*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(3-hydroxyphenyl)oxyphenyl)urea;  
*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(4-acetylphenyl)oxyphenyl)urea;  
*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-benzoylphenyl)urea;  
*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-phenyloxyphenyl)urea;  
*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(3-methylaminocarbonylphenyl)-thiophenyl)urea;  
*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(4-(1,2-methylenedioxy)phenyl)-oxyphenyl)urea;  
*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(3-pyridinyl)oxyphenyl)urea;  
*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(4-pyridinyl)oxyphenyl)urea;  
*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(4-pyridyl)thiophenyl)urea;  
*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-(4-pyridinyl)oxyphenyl)urea;  
*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-(4-pyridinyl)thiophenyl)urea;  
*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-(3-methyl-4-pyridinyl)oxyphenyl)urea;  
*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-(3-methyl-4-pyridinyl)thiophenyl)urea;  
*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(3-methyl-4-pyridinyl)thiophenyl)urea;  
*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-(4-methyl-3-pyridinyl)oxyphenyl)urea; and  
*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(3-methyl-4-pyridinyl)oxyphenyl)urea;  
and pharmaceutically acceptable salts thereof.

12. (Previously Presented) A method as in claim 9, wherein R<sup>1</sup> is *t*-butyl.

13. (Original) A method as in claim 1 comprising administering a compound of the formula



wherein R<sup>1</sup> and B are as defined in claim 1.


14. (Cancelled)

15. (Previously Presented) A method as in claim 1 comprising administering a compound selected from the group consisting of  
*N*-(3-Isopropyl-5-isoxazolyl)-*N'*-(4-(4-pyridinyl)thiophenyl)urea;  
*N*-(3-*tert*-Butyl-5-isoxazolyl)-*N'*-(4-(4-methoxyphenyl)oxyphenyl)urea;  
*N*-(3-*tert*-Butyl-5-isoxazolyl)-*N'*-(3-(4-pyridinyl)thiophenyl)urea;  
*N*-(3-*tert*-Butyl-5-isoxazolyl)-*N'*-(4-(4-pyridinyl)thiophenyl)urea;  
*N*-(3-*tert*-Butyl-5-isoxazolyl)-*N'*-(4-(4-pyridinyl)oxyphenyl)urea;  
*N*-(3-*tert*-Butyl-5-isoxazolyl)-*N'*-(4-(4-methyl-3-pyridinyl)oxyphenyl)urea;  
*N*-(3-(1,1-Dimethylpropyl)-5-isoxazolyl)-*N'*-(4-(4-methylphenyl)oxyphenyl)urea;  
*N*-(3-(1,1-Dimethylpropyl)-5-isoxazolyl)-*N'*-(3-(4-pyridinyl)thiophenyl)urea;  
*N*-(3-(1,1-Dimethylpropyl)-5-isoxazolyl)-*N'*-(4-(4-pyridinyl)oxyphenyl)urea;  
*N*-(3-(1,1-Dimethylpropyl)-5-isoxazolyl)-*N'*-(4-(4-pyridinyl)thiophenyl)urea;  
*N*-(3-(1-Methyl-1-ethylpropyl)-5-isoxazolyl)-*N'*-(4-(4-pyridinyl)oxyphenyl)urea; and  
*N*-(3-(1-Methyl-1-ethylpropyl)-5-isoxazolyl)-*N'*-(3-(4-pyridinyl)thiophenyl)urea;  
and pharmaceutically acceptable salts thereof.

16. (Original) A method as in claim 13, wherein R<sup>1</sup> is *t*-butyl.

17-36. (Cancelled)

37. (Previously Presented) A compound of the formula



wherein R<sup>1</sup> is selected from the group consisting of C<sub>3</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, up to per-halosubstituted C<sub>3</sub>-C<sub>6</sub> alkyl and up to per-halosubstituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl;

B is phenyl substituted by X, and optionally substituted by halogen, up to per-

halosubstitution, and optionally substituted by  $X^1_n$  wherein  $n = 0-2$ ;

each  $X^1$  is independently selected from the group of X or from the group consisting of  $-\text{CN}$ ,  $-\text{CO}_2\text{R}^5$ ,  $-\text{C}(\text{O})\text{R}^5$ ,  $-\text{C}(\text{O})\text{NR}^5\text{R}^{5'}$ ,  $-\text{OR}^5$ ,  $-\text{NO}_2$ ,  $-\text{NR}^5\text{R}^{5'}$ ,  $\text{C}_1\text{-C}_{10}$  alkyl,  $\text{C}_{2-10}$ -alkenyl,  $\text{C}_{1-10}$ -alkoxy,  $\text{C}_3\text{-C}_{10}$  cycloalkyl, and  $\text{C}_6\text{-C}_{14}$  and


X is  $-\text{Y-Ar}$ ,

wherein if X is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of  $-\text{CN}$ ,  $-\text{CO}_2\text{R}^5$ ,  $-\text{C}(\text{O})\text{R}^5$ ,  $-\text{C}(\text{O})\text{NR}^5\text{R}^{5'}$ ,  $-\text{OR}^5$ ,  $-\text{SR}^5$ ,  $-\text{NR}^5\text{R}^{5'}$ ,  $\text{NO}_2$ ,  $-\text{NR}^5\text{C}(\text{O})\text{R}^{5'}$ ,  $-\text{NR}^5\text{C}(\text{O})\text{OR}^{5'}$  and halogen up to per-halosubstitution;


wherein  $\text{R}^5$  and  $\text{R}^{5'}$  are independently selected from H,  $\text{C}_1\text{-C}_{10}$  alkyl,  $\text{C}_{2-10}$ -alkenyl,  $\text{C}_3\text{-C}_{10}$  cycloalkyl,  $\text{C}_6\text{-C}_{14}$  aryl,  $\text{C}_3\text{-C}_{13}$  heteroaryl,  $\text{C}_7\text{-C}_{24}$  alkaryl,  $\text{C}_4\text{-C}_{23}$  alkheteroaryl, up to per-halosubstituted  $\text{C}_1\text{-C}_{10}$  alkyl, up to per-halosubstituted  $\text{C}_{2-10}$ -alkenyl, and up to per-halosubstituted  $\text{C}_3\text{-C}_{10}$  cycloalkyl,

Y is  $-\text{O}-$ , or  $-\text{S}-$ , and

Ar is phenyl, or pyridinyl, which is unsubstituted or substituted by halogen up to per-halo and optionally substituted by  $\text{Z}_{n1}$ , wherein  $n1$  is 0 to 3 and each Z is independently selected from the group consisting of  $-\text{CN}$ ,  $-\text{CO}_2\text{R}^5$ ,  $-\text{C}(\text{O})\text{R}^5$ ,  $=\text{O}$ ,  $-\text{C}(\text{O})\text{NR}^5\text{R}^{5'}$ ,  $-\text{C}(\text{O})\text{R}^5$ ,  $-\text{NO}_2$ ,  $-\text{OR}^5$ ,  $-\text{SR}^5$ ,  $-\text{NR}^5\text{R}^{5'}$ ,  $-\text{NR}^5\text{C}(\text{O})\text{OR}^{5'}$ ,  $-\text{NR}^5\text{C}(\text{O})\text{R}^{5'}$ ,  $-\text{SO}_2\text{R}^5$ ,  $-\text{SO}_2\text{R}^5\text{R}^{5'}$ ,  $\text{C}_1\text{-C}_{10}$  alkyl,  $\text{C}_1\text{-C}_{10}$  alkoxy,  $\text{C}_3\text{-C}_{10}$  cycloalkyl, substituted  $\text{C}_1\text{-C}_{10}$  alkyl, and substituted  $\text{C}_3\text{-C}_{10}$  cycloalkyl, wherein if Z is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of  $-\text{CN}$ ,  $-\text{CO}_2\text{R}^5$ ,  $-\text{C}(\text{O})\text{NR}^5\text{R}^{5'}$ ,  $=\text{O}$ ,  $-\text{OR}^5$ ,  $-\text{SR}^5$ ,  $-\text{NO}_2$ ,  $-\text{NR}^5\text{R}^{5'}$ ,  $-\text{NR}^5\text{C}(\text{O})\text{R}^{5'}$ ,  $-\text{NR}^5\text{C}(\text{O})\text{OR}^{5'}$ ,  $\text{C}_1\text{-C}_{10}$  alkyl,  $\text{C}_1\text{-C}_{10}$  alkoxyl, and  $\text{C}_3\text{-C}_{10}$  cycloalkyl, subject to the proviso that where  $\text{R}^1$  is t-butyl, B is not



wherein  $\text{R}^6$  is  $-\text{NHC}(\text{O})-\text{O-t-butyl}$ ,  $-\text{O-n-pentyl}$ ,  $-\text{O-n-butyl}$ ,  $-\text{O-n-propyl}$ ,  $-\text{C}(\text{O})\text{NH}-(\text{CH}_3)_2$ ,  $-\text{OCH}_2\text{CH}(\text{CH}_3)_2$ , or



38-40. (Cancelled)

41. (Withdrawn) A compound as in claim 37 selected from the group consisting of:

*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(4-hydroxyphenyl)oxyphenyl)urea;  
*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(3-hydroxyphenyl)oxyphenyl)urea;  
*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(4-acetylphenyl)oxyphenyl)urea;  
*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-phenyloxyphenyl)urea;  
*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(3-methylaminocarbonylphenyl)-thiophenyl)urea;  
*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(4-(1,2-methylenedioxy)phenyl)-oxyphenyl)urea;  
*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(3-pyridinyl)oxyphenyl)urea;  
*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(4-pyridinyl)oxyphenyl)urea;  
*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(4-pyridyl)thiophenyl)urea;  
*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-(4-pyridinyl)oxyphenyl)urea;  
*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-(4-pyridinyl)thiophenyl)urea;  
*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-(3-methyl-4-pyridinyl)oxyphenyl)urea;  
*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-(3-methyl-4-pyridinyl)thiophenyl)urea;  
*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(3-methyl-4-pyridinyl)thiophenyl)urea;  
*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-(4-methyl-3-pyridinyl)oxyphenyl)urea;  
*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(3-methyl-4-pyridinyl)oxyphenyl)urea;  
*N*-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(3-chloro-4-(4-(2-methylcarbamoyl)pyridyl)-

oxyphenyl) urea;

*N*-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(4-(4-(2-methylcarbamoyl)pyridyl)-oxyphenyl) urea;  
*N*-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(3-(4-(2-methylcarbamoyl)pyridyl)-thiophenyl) urea;  
*N*-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(2-methyl-4-(4-(2-methylcarbamoyl)pyridyl)-

oxyphenyl) urea;


*N*-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(4-(4-(2-carbamoyl)pyridyl)oxyphenyl) urea;  
*N*-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(3-(4-(2-carbamoyl)pyridyl)oxyphenyl) urea;  
*N*-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(3-(4-(2-methylcarbamoyl)pyridyl)-oxyphenyl) urea;  
*N*-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(4-(4-(2-methylcarbamoyl)pyridyl)-thiophenyl) urea;  
*N*-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(3-chloro-4-(4-(2-methylcarbamoyl)pyridyl)-

oxyphenyl) urea; and

*N*-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(4-(3-methylcarbamoyl)phenyl)oxyphenyl) urea;


and pharmaceutically acceptable salts thereof.

42. (Withdrawn and Currently Amended) A compound according to claim 37, which is of the formula



wherein B is as defined in claim 37.

43. (Previously Presented) A compound of the formula



wherein R<sup>1</sup> is selected from the group consisting of C<sub>3</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, up to per-halosubstituted C<sub>3</sub>-C<sub>6</sub> alkyl, and up to per-halosubstituted C<sub>3</sub>-C<sub>6</sub> cycloalkyl, and

B is phenyl, which is substituted by X, and optionally substituted by halogen, up to per-halosubstitution, and optionally substituted by X<sup>1</sup><sub>n</sub>, wherein n = 0-2;

each X<sup>1</sup> is independently selected from the group of X or from the group consisting of -CN, -CO<sub>2</sub>R<sup>5</sup>, -C(O)R<sup>5</sup>, -C(O)NR<sup>5</sup>R<sup>5'</sup>, -OR<sup>5</sup>, -NO<sub>2</sub>, -NR<sup>5</sup>R<sup>5'</sup>, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>2-10</sub>-alkenyl, C<sub>1-10</sub>-alkoxy, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, C<sub>6</sub>-C<sub>14</sub> aryl and C<sub>7</sub>-C<sub>24</sub> alkaryl, and

X is -Y-Ar, and wherein if X is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of -CN, CO<sub>2</sub>R<sup>5</sup>, -C(O)R<sup>5</sup>, -C(O)NR<sup>5</sup>R<sup>5'</sup>, -OR<sup>5</sup>, -SR<sup>5</sup>, -NR<sup>5</sup>R<sup>5'</sup>, NO<sub>2</sub>, -NR<sup>5</sup>C(O)R<sup>5'</sup>, -NR<sup>5</sup>C(O)OR<sup>5'</sup> and halogen up to per-halosubstitution;

wherein R<sup>5</sup> and R<sup>5'</sup> are independently selected from H, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>2-10</sub>-alkenyl, C<sub>3-10</sub> cycloalkyl, C<sub>6</sub>-C<sub>14</sub> aryl, C<sub>3</sub>-C<sub>13</sub> heteroaryl, C<sub>7</sub>-C<sub>24</sub> alkaryl, C<sub>4</sub>-C<sub>23</sub> alkheteroaryl, up to per-


halosubstituted C<sub>1</sub>-C<sub>10</sub> alkyl, up to per-halosubstituted C<sub>2-10</sub>-alkenyl, and up to per-halosubstituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl, wherein

Y is - O-, or -S-,

Ar is phenyl, or pyridinyl, which is unsubstituted or substituted by halogen up to per-halo and optionally substituted by Z<sub>n1</sub>, wherein n1 is 0 to 3 and each Z is independently selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>5</sup>, -C(O)R<sup>5</sup>, =O, -C(O)NR<sup>5</sup>R<sup>5'</sup>, -C(O)R<sup>5</sup>, -NO<sub>2</sub>, -OR<sup>5</sup>, -SR<sup>5</sup>, -NR<sup>5</sup>R<sup>5'</sup>, -NR<sup>5</sup>C(O)OR<sup>5'</sup>, -NR<sup>5</sup>C(O)R<sup>5'</sup>, -SO<sub>2</sub>R<sup>5</sup>, -SO<sub>2</sub>R<sup>5</sup>R<sup>5'</sup>, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, substituted C<sub>1</sub>-C<sub>10</sub> alkyl, and substituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl, wherein if Z is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>5</sup>, -C(O)NR<sup>5</sup>R<sup>5'</sup>, =O, -OR<sup>5</sup>, -SR<sup>5</sup>, -NO<sub>2</sub>, -NR<sup>5</sup>R<sup>5'</sup>, -NR<sup>5</sup>C(O)R<sup>5'</sup> and -NR<sup>5</sup>C(O)OR<sup>5'</sup>, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, and C<sub>3</sub>-C<sub>10</sub> cycloalkyl,


and where R<sup>1</sup> is -CH<sub>2</sub>-t-butyl,

B is not



44-45. (Cancelled)

46. (Currently Amended) A compound according to claim 43, which is of the formula



wherein B is as defined in claim 43.

47-79. (Cancel)

80. (Previously Presented) A method according to claim 1, wherein the cancerous cell growth is mediated by raf kinase.



81. (New) A method according to claim 1, wherein R<sup>1</sup> is selected from the group consisting of halogen, C<sub>3</sub>-C<sub>10</sub> alkyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, C<sub>6-14</sub> aryl, C<sub>7-24</sub> alkaryl, up to per-halosubstituted C<sub>1</sub>-C<sub>10</sub> alkyl, up to per-halosubstituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl, up to per-halosubstituted C<sub>6-14</sub> aryl, and up to per-halosubstituted C<sub>7-24</sub> alkaryl.